A detailed history of Catalina Capital Group, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Catalina Capital Group, LLC holds 13,600 shares of SAVA stock, worth $34,272. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,600
Holding current value
$34,272
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 24, 2025

BUY
$2.29 - $32.18 $31,144 - $437,648
13,600 New
13,600 $32.1 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $101M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Catalina Capital Group, LLC Portfolio

Follow Catalina Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalina Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalina Capital Group, LLC with notifications on news.